NBP
NovaBridge Biosciences
Biotechnology
Market Cap$416M
5Y Perf.-91.1%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
NBP vs IMVT
Revenue, margins, valuation, and 5-year total return — side by side.
IMVT
Immunovant, Inc.
Biotechnology
Market Cap$5.53B
5Y Perf.+6.1%
NBP vs IMVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | NBP | IMVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $416M | $5.53B |
| Revenue (TTM) | $0.00 | $0.00 |
| Net Income (TTM) | $-25M | $-464M |
| Total Debt | $4M | $98K |
| Cash & Equiv. | $68M | $714M |
NBP vs IMVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
NBP
IMVT
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| NovaBridge Bioscien… (NBP) | 100 | 8.9 | -91.1% |
| Immunovant, Inc. (IMVT) | 100 | 106.1 | +6.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: NBP vs IMVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NBP leads in 4 of 6 categories, making it the strongest pick for profitability and margin quality and capital preservation and lower volatility. Immunovant, Inc. is the stronger pick specifically for growth and revenue expansion. As sector peers, any of these can serve as alternatives in the same allocation.
NBP
NovaBridge Biosciences
The Income Pick
NBP carries the broadest edge in this set and is the clearest fit for income & stability and growth exposure.
- Dividend streak 1 yrs, beta 1.25
- Rev growth -100.0%, EPS growth 74.7%
- Lower volatility, beta 1.25, Low D/E 1.9%, current ratio 20.90x
Best for: income & stability and growth exposure
IMVT
Immunovant, Inc.
The Long-Run Compounder
IMVT is the clearest fit if your priority is long-term compounding.
- 173.6% 10Y total return vs NBP's -82.2%
- -21.3% revenue growth vs NBP's -100.0%
Best for: long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMVT | -21.3% revenue growth vs NBP's -100.0% |
| Quality / Margins | NBP | 25.7% margin vs IMVT's 3.2% |
| Stability / Safety | NBP | Beta 1.25 vs IMVT's 1.37 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | NBP | +149.4% vs IMVT's +96.1% |
| Efficiency (ROA) | NBP | -8.8% ROA vs IMVT's -44.1% |
NBP vs IMVT — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2023
Segment breakdown not available.
NBP vs IMVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNBPLAGGINGIMVT
IMVTImmunovant, Inc.
2leads
NBPNovaBridge Biosciences
2leads
6 Total Categories
CATEGORYLEADERvs IMVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NBP1/1
Valuation MetricsMultiples, price ratios, and targets
IMVT2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NBP4/7
Total Returns1Y, 3Y, 5Y total returns with dividends
IMVT5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NBP leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
NBP and IMVT operate at a comparable scale, with $0 and $0 in trailing revenue.
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $0 | $0 |
| EBITDAEarnings before interest/tax | -$33M | -$487M |
| Net IncomeAfter-tax profit | -$25M | -$464M |
| Free Cash FlowCash after capex | $2M | -$423M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | — | — |
| Net MarginNet income ÷ Revenue | — | — |
| FCF MarginFCF ÷ Revenue | — | — |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +73.0% | +19.7% |
NBP leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
IMVT leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| Market CapShares × price | $416M | $5.5B |
| Enterprise ValueMkt cap + debt − cash | $407M | $4.8B |
| Trailing P/EPrice ÷ TTM EPS | -3.39x | -9.97x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | — |
| Price / BookPrice ÷ Book value/share | 6.10x | 5.83x |
| Price / FCFMarket cap ÷ FCF | — | — |
IMVT leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NBP leads this category, winning 4 of 7 comparable metrics.
Profitability & Efficiency
NBP delivers a -9.5% return on equity — every $100 of shareholder capital generates $-9 in annual profit, vs $-47 for IMVT. IMVT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to NBP's 0.02x. On the Piotroski fundamental quality scale (0–9), NBP scores 5/9 vs IMVT's 2/9, reflecting solid financial health.
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -9.5% | -47.1% |
| ROA (TTM)Return on assets | -8.8% | -44.1% |
| ROICReturn on invested capital | — | — |
| ROCEReturn on capital employed | -31.2% | -66.1% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.02x | 0.00x |
| Net DebtTotal debt minus cash | -$64M | -$714M |
| Cash & Equiv.Liquid assets | $68M | $714M |
| Total DebtShort + long-term debt | $4M | $98,000 |
| Interest CoverageEBIT ÷ Interest expense | — | — |
NBP leads this category, winning 4 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
IMVT leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMVT five years ago would be worth $16,241 today (with dividends reinvested), compared to $374 for NBP. Over the past 12 months, NBP leads with a +149.4% total return vs IMVT's +96.1%. The 3-year compound annual growth rate (CAGR) favors IMVT at 12.1% vs NBP's -9.7% — a key indicator of consistent wealth creation.
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -48.0% | +5.1% |
| 1-Year ReturnPast 12 months | +149.4% | +96.1% |
| 3-Year ReturnCumulative with dividends | -26.5% | +40.9% |
| 5-Year ReturnCumulative with dividends | -96.3% | +62.4% |
| 10-Year ReturnCumulative with dividends | -82.2% | +173.6% |
| CAGR (3Y)Annualised 3-year return | -9.7% | +12.1% |
IMVT leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — NBP and IMVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
NBP is the less volatile stock with a 1.25 beta — it tends to amplify market swings less than IMVT's 1.37 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMVT currently trades 90.5% from its 52-week high vs NBP's 32.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.25x | 1.37x |
| 52-Week HighHighest price in past year | $6.79 | $30.09 |
| 52-Week LowLowest price in past year | $0.83 | $13.36 |
| % of 52W HighCurrent price vs 52-week peak | +32.7% | +90.5% |
| RSI (14)Momentum oscillator 0–100 | 35.1 | 60.2 |
| Avg Volume (50D)Average daily shares traded | 1.0M | 1.4M |
Evenly matched — NBP and IMVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates NBP as "Buy" and IMVT as "Buy". Consensus price targets imply 305.4% upside for NBP (target: $9) vs 67.2% for IMVT (target: $46).
| Metric | NBPNovaBridge Biosci… | IMVTImmunovant, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $9.00 | $45.50 |
| # AnalystsCovering analysts | 11 | 23 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NBP leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). IMVT leads in 2 (Valuation Metrics, Total Returns). 1 tied.
Best OverallNovaBridge Biosciences (NBP)Leads 2 of 6 categories
Loading custom metrics...
NBP vs IMVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is NBP or IMVT a better buy right now?
Analysts rate NovaBridge Biosciences (NBP) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison.
The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — NBP or IMVT?
Over the past 5 years, Immunovant, Inc.
(IMVT) delivered a total return of +62. 4%, compared to -96. 3% for NovaBridge Biosciences (NBP). Over 10 years, the gap is even starker: IMVT returned +173. 6% versus NBP's -82. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — NBP or IMVT?
By beta (market sensitivity over 5 years), NovaBridge Biosciences (NBP) is the lower-risk stock at 1.
25β versus Immunovant, Inc. 's 1. 37β — meaning IMVT is approximately 10% more volatile than NBP relative to the S&P 500. On balance sheet safety, Immunovant, Inc. (IMVT) carries a lower debt/equity ratio of 0% versus 2% for NovaBridge Biosciences — giving it more financial flexibility in a downturn.
04Which is growing faster — NBP or IMVT?
On earnings-per-share growth, the picture is similar: NovaBridge Biosciences grew EPS 74.
7% year-over-year, compared to -45. 2% for Immunovant, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — NBP or IMVT?
NovaBridge Biosciences (NBP) is the more profitable company, earning 0.
0% net margin versus 0. 0% for Immunovant, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NBP leads at 0. 0% versus 0. 0% for IMVT. At the gross margin level — before operating expenses — NBP leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — NBP or IMVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is NBP or IMVT better for a retirement portfolio?
For long-horizon retirement investors, Immunovant, Inc.
(IMVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (+173. 6% 10Y return). Both have compounded well over 10 years (IMVT: +173. 6%, NBP: -82. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between NBP and IMVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.